GLP-1 medications represent a hope in the fight against obesity; however, misinformation about and misuse of these medications abound. For optimal results in managing obesity, it is important to combine GLP-1 medications’ intake with lifestyle changes.
This was a major theme in a discussion about obesity at Becker’s Payer Issues Roundtable, led by Linda Anegawa, MD, chief medical officer at Noom.
Four key takeaways were:
1. GLP-1 drugs have multiple benefits. GLP-1 medications are effective due to their dual mechanism of action: stimulates insulin release from the pancreas in response to dietary glucose/carbohydrates and then delays gastric emptying and reduces food intake by direct action on receptors in the hypothalamus (hunger center of the brain). “Beyond the impact in the gut . . . the beneficial effects go way beyond. We’re only at the tip of the iceberg of learning about these beneficial effects,” Dr. Anegawa said.
2. GLP-1 medications can be effective in weight loss, but they should be combined with behavior change interventions. Proper nutrition and physical activity are crucial to realizing the promise of GLP-1 medications sustainably. In 2018, Noom offered a support program to 65,000 early-stage GLP-1 users, whereby Noom offered personalized programs introducing nutrition and exercise habits to those taking GLP-1s. The program was very successful. At six months, users using Noom + GLP-1 experienced 3x more weight loss; at 12 months, that same group experienced 6x more weight loss. “Changing behavior is essential to maximizing outcomes,” Dr. Anegawa highlighted. “If you use Noom and you take a GLP-1 medication, you’re going to lose the most weight of any group.”
3. Personalized care plans and support tools are crucial for successful weight loss and maintenance. Noom’s psychology-based offering includes a detailed questionnaire and evaluation of each user’s metabolic needs in order to develop a customized care plan, which is then followed by periodic adjustments, based on user response.
“It [Noom] personalizes the offering, it builds commitment and momentum — and we found that by tweaking things, we were able to improve retention and user engagement,” Dr. Anegawa said. Noom’s offering also includes a food lookup tool, mini-courses and conversations, and a non-judgmental weight feedback tool.
4. Access to GLP-1 medications should be based on individual needs, not solely BMI. There are many factors beyond an individual’s body mass index that affect their weight; that’s why prescribing GLP-1 medications based on weight alone is inappropriate, Dr. Anegawa said. “Treating by BMI alone and having BMI be the sole or main qualifying criteria is absolutely wrong.”
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
